Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Soo-Kyung | - |
dc.contributor.author | Kim, Hyoungyoung | - |
dc.contributor.author | Song, Yeo-Jin | - |
dc.contributor.author | Kim, Hye Won | - |
dc.contributor.author | Nam, Eunwoo | - |
dc.contributor.author | Lee, Shin-Seok | - |
dc.contributor.author | Lee, Hye-Soon | - |
dc.contributor.author | Park, Sung-Hoon | - |
dc.contributor.author | Lee, Yeon-Ah | - |
dc.contributor.author | Park, Min-Chan | - |
dc.contributor.author | Chang, Sung Hae | - |
dc.contributor.author | Kim, Hyoun-Ah | - |
dc.contributor.author | Kwok, Seung-Ki | - |
dc.contributor.author | Kim, Hae-Rim | - |
dc.contributor.author | Kim, Hyun-Sook | - |
dc.contributor.author | Yoon, Bo Young | - |
dc.contributor.author | Uhm, Wan-Sik | - |
dc.contributor.author | Kim, Yong-Gil | - |
dc.contributor.author | Kim, Jae Hoon | - |
dc.contributor.author | Lee, Jisoo | - |
dc.contributor.author | Choi, Jeongim | - |
dc.contributor.author | Sung, Yoon-Kyoung | - |
dc.date.accessioned | 2023-12-13T13:01:06Z | - |
dc.date.available | 2023-12-13T13:01:06Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.issn | 2005-6648 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/24943 | - |
dc.description.abstract | Background/Aims: We aimed to compare the effectiveness and safety of Janus kinase inhibitors (JAKi) vs. biologic disease-modifying antirheumatic drugs (bDMARD) in Korean patients with rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic DMARDs.Methods: A quasi-experimental, multi-center, prospective, non-randomized study was conducted to compare response rates between JAKi and bDMARDs in patients with RA naive to targeted therapy. An interim analysis was performed to estimate the proportion of patients achieving low disease activity (LDA) based on disease activity score (DAS)-28- erythroid sedimentation rate (ESR) (DAS28-ESR) at 24 weeks after treatment initiation and to evaluate the development of adverse events (AEs).Results: Among 506 patients enrolled from 17 institutions between April 2020 and August 2022, 346 (196 JAKi group and 150 bDMARD group) were included in the analysis. After 24 weeks of treatment, 49.0% of JAKi users and 48.7% of bDMARD users achieved LDA (p = 0.954). DAS28-ESR remission rates were also comparable between JAKi and bDMARD users (30.1% and 31.3%, respectively; p = 0.806). The frequency of AEs reported in the JAKi group was numerically higher than that in the bDMARDs group, but the frequencies of serious and severe AEs were comparable between the groups.Conclusions: Our interim findings reveal JAKi have comparable effectiveness and safety to bDMARDs at 24 weeks after treatment initiation. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한내과학회 | - |
dc.title | Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3904/kjim.2022.369 | - |
dc.identifier.scopusid | 2-s2.0-85164262834 | - |
dc.identifier.wosid | 001014646100001 | - |
dc.identifier.bibliographicCitation | The Korean Journal of Internal Medicine, v.38, no.4, pp 546 - + | - |
dc.citation.title | The Korean Journal of Internal Medicine | - |
dc.citation.volume | 38 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 546 | - |
dc.citation.endPage | + | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | HEAD-TO-HEAD | - |
dc.subject.keywordPlus | TOFACITINIB MONOTHERAPY | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | ADALIMUMAB | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | CP-690,550 | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | Janus kinase inhibitor | - |
dc.subject.keywordAuthor | Tumor necrosis factor inhibitors | - |
dc.subject.keywordAuthor | Comparative effectiveness research | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.